The Zhitong Finance App learned that on Monday, Cytokinetics (CYTK.US) surged more than 10%, continuing to reach a new high during the year, and is now at $69.34. According to the news, recently, the China Drug Administration approved the marketing of the Class 1 innovative drug Avcatel tablets (trade name: xingshupin) declared by Cytokinetics, Incorporated. The drug is used to treat adult patients with obstructive hypertrophic cardiomyopathy (HCM) with grade II-III cardiac function classification by the New York Heart Association (NYHA) to improve motor ability and symptoms.

The Zhitong Finance App learned that on Monday, Cytokinetics (CYTK.US) surged more than 10%, continuing to reach a new high during the year, and is now at $69.34. According to the news, recently, the China Drug Administration approved the marketing of the Class 1 innovative drug Avcatel tablets (trade name: xingshupin) declared by Cytokinetics, Incorporated. The drug is used to treat adult patients with obstructive hypertrophic cardiomyopathy (HCM) with grade II-III cardiac function classification by the New York Heart Association (NYHA) to improve motor ability and symptoms.